Bergen, Norway, 14 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, is pleased to announce that the Company will present its recently initiated Phase II clinical trial investigating BGB324 in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD … Read more
Bergen, Norway, 10 November 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, will announce its results for the third quarter 2017 on Friday, 17 November 2017. A presentation by BerGenBio’s senior management team will take place at 9.00 am CET at: Thon Hotel Vika Atrium, … Read more
Bergen, Norway, 1 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that data and analysis from its Phase Ib/II clinical trial with BGB324 in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), has been selected for presentation at the 59th … Read more
Bergen, Norway, 24 Oct 2017 – BerGenBio ASA (OSE: BGBIO) ( http://www.bergenbio.com ), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, announces that the first patient has been dosed in a Phase II trial evaluating the Company’s lead product BGB324 in combination with KEYTRUDA® (pembrolizumab) in patients … Read more
Bergen, Norway, 19 October 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, announces that the first patient has been dosed in a Phase II trial evaluating the Company’s lead product BGB324 in combination with KEYTRUDA® (pembrolizumab) in patients … Read more
Bergen, Norway, October 18, 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the randomised Phase 1b/2 clinical study of BGB324 in combination with either the MAPK inhibitors MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or the immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) in patients with … Read more
Bergen, Norway, October 16, 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces presentations on three ongoing Phase 2 clinical trials with BGB324 in lung cancer patients at the 18th World Conference on Lung Cancer in Yokohama, Japan. BGB324, a first-in-class selective Axl inhibitor, … Read more
Bergen, Norway, Oct 12 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the clinical trial of BGB324 in combination with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA® in advanced melanoma, will be presented at the 9th World Congress of Melanoma in … Read more
Bergen, Norway, Sep 28 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors ( http://www.bergenbio.com ) for multiple cancer indications, is pleased to announce that the Company will present three ongoing lung cancer clinical trials with BGB324 at the 18th World Conference on Lung Cancer in Yokohama, Japan, October 15 … Read more
Bergen, Norway, 18 August 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the second quarter and half year 2017. A presentation of the results by the Company’s senior management team will take place today at 10.00 am CEST in Oslo – … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.